EAST-ASIA PHARMACEUTICAL: Lu Li Kang Zuo raw materials have obtained the raw material drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.
EAST-ASIA PHARMACEUTICAL announced that its Luliconazole active pharmaceutical ingredient has obtained the registration certificate from the Korea Food and Drug Administration. This certification marks the product's eligibility for entry into the South Korean market, which will positively impact the company's expansion in the pharmaceutical market in South Korea and promote the sales of Luliconazole in other overseas markets
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments